When Pfizer dropped $10 billion to acquire Metsera in 2025, it was one of the largest deals in the obesity drug space. The message was clear: Pfizer wanted in on the weight loss market, and it was willing to pay a premium to get there.
At the American Diabetes Association’s annual meeting this month, we got the first real look at whether that investment makes sense.
What Pfizer Got for $10 Billion
Metsera’s pipeline centres on next-generation weight loss medicines designed to address some of the limitations of current treatments. The flagship compound is berobenatide, which has a key differentiator: it could potentially be dosed less frequently than existing obesity drugs.
For context, semaglutide (Wegovy) is a weekly injection. Tirzepatide (Zepbound) is also weekly. If berobenatide can deliver comparable results with monthly or even less frequent dosing, that’s a genuine advantage - particularly for people who find weekly injections burdensome.
Pfizer presented Phase 2 data for berobenatide at ADA 2026. While the full dataset is still being digested by analysts, the early signal suggests the compound has potential, though questions remain about how it stacks up against Lilly’s dominant portfolio.
Why Pfizer Needed a New Approach
Pfizer’s previous attempt at an obesity drug didn’t go well. The company had been developing danuglipron, an oral GLP-1 agonist, but pulled the plug after disappointing Phase 2 results. Daily dosing with significant gastrointestinal side effects wasn’t going to compete in a market where weekly injections were already delivering 20%+ weight loss.
The Metsera acquisition was essentially Pfizer starting over with a different playbook. Rather than trying to develop a compound from scratch, they bought a pipeline that was already in clinical testing.
The Competitive Landscape
The timing of Pfizer’s entry is both a challenge and an opportunity. The challenge is obvious: Eli Lilly and Novo Nordisk have massive head starts. Zepbound and Wegovy are already generating billions in revenue, and Lilly’s retatrutide just showed 28% weight loss at ADA 2026 - numbers that approach bariatric surgery.
But the opportunity is equally clear. The obesity drug market is projected to reach $100 billion globally within the next decade. There’s room for multiple players, particularly if they can offer something different.
That’s where berobenatide’s less frequent dosing could matter. If the efficacy data holds up in Phase 3, a compound that works as well as current treatments but requires fewer injections could carve out a meaningful niche.
What the Research Says
The Phase 2 data presented at ADA 2026 showed that berobenatide produced dose-dependent weight loss in participants with obesity. Analysts at Jefferies noted the results were encouraging but emphasised that Phase 2 data needs to be confirmed in larger, longer Phase 3 trials.
Pfizer is expected to advance berobenatide into Phase 3 testing later this year. The company has indicated it views the compound as a “foundational” asset for its obesity franchise - language that suggests they’re planning to build a broader portfolio around it.
The Bigger Picture
Pfizer’s $10 billion bet reflects a broader trend: the obesity drug market is attracting unprecedented investment. Companies that missed the first wave are now paying premium prices to get into the game.
Other notable developments from ADA 2026 reinforce this. Roche presented data on enicepatide, though analysts described it as more of a “me-too” option. AstraZeneca recently announced it’s advancing its oral GLP-1 pill elecoglipron into Phase 3. And smaller biotechs are raising record IPOs on the strength of their obesity pipelines.
For the research community, this competition is broadly positive. More companies investing in obesity research means more clinical trials, more data, and ultimately more options for understanding these compounds.
What to Watch
The key milestones for Pfizer’s obesity pipeline in the coming months:
- Phase 3 trial design for berobenatide - expected to be announced in the second half of 2026
- Dosing frequency confirmation - whether less frequent dosing delivers comparable efficacy
- Combination strategy - whether Pfizer plans to pair berobenatide with other compounds
- Timeline to market - realistic expectations are 2028-2029 at the earliest
We’ll be tracking these developments closely. The obesity drug space is moving fast, and Pfizer’s $10 billion entry adds another major player to an already crowded field.
This article is for educational and informational purposes only. It does not constitute medical advice, therapeutic recommendations, or endorsements of any compound. Grey Highway is a research-education community. We do not sell, supply, or promote the use of research compounds. Always consult a qualified healthcare professional regarding health decisions. For Australian regulatory information, visit the TGA website.
Sources
- BioPharma Dive: “ADA ‘26: Lilly’s dominance, Pfizer’s ‘foundational’ drug and Roche’s ‘me-too’ option” (8 June 2026) - biopharmadive.com
- Pfizer/Metsera acquisition - $10 billion deal announced 2025
- ADA 2026 Scientific Sessions, Chicago, June 2026